OmniAb (OABI) Research & Development (2022 - 2026)
OmniAb (OABI) reported Research & Development of $9.6 million for Q1 2026, down 23.5% year-over-year from $12.6 million in Q1 2025, and down 30.69% quarter-over-quarter from $13.9 million in Q4 2025.
OmniAb (OABI) Research & Development (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Research & Development data on file, last reported at $9.6 million in Q1 2026.
- Research & Development for Q1 2026 came in at $9.6 million, down 23.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.8 million (down 15.74% YoY), and the FY2025 annual result was $47.8 million, down 13.35% from the prior year.
- Research & Development declined to $9.6 million in Q1 2026 per OABI's latest filing, from $13.9 million in the prior quarter.
- Over five years, Research & Development peaked at $14.8 million in Q4 2023 and troughed at $9.6 million in Q1 2026.
- A 5-year average of $12.8 million and a median of $13.3 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2026: Research & Development advanced 27.73% in 2023, then declined 23.5% in 2026.
- A 5-year view of Research & Development shows it stood at $12.9 million in 2022, then climbed by 14.3% to $14.8 million in 2023, then declined by 9.89% to $13.3 million in 2024, then advanced by 4.53% to $13.9 million in 2025, then plunged by 30.69% to $9.6 million in 2026.
- Business Quant data shows OABI's Research & Development at $9.6 million in Q1 2026, $13.9 million in Q4 2025, and $10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 9.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.64 Mn |
| Dec 31, 2025 | 13.91 Mn |
| Sep 30, 2025 | 10.38 Mn |
| Jun 30, 2025 | 10.86 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | 13.32 Mn |
| Jun 30, 2024 | 13.94 Mn |
| Mar 31, 2024 | 14.55 Mn |
| Dec 31, 2023 | 14.77 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 14.13 Mn |
| Mar 31, 2023 | 13.76 Mn |
| Dec 31, 2022 | 12.92 Mn |
| Sep 30, 2022 | 13.19 Mn |
| Jun 30, 2022 | 11.48 Mn |
| Mar 31, 2022 | 10.77 Mn |